Cocrystal pharma granted european patent covering oral antiviral candidate cc-42344 in combination with another antiviral agent for the treatment of influenza

Bothell, wash., nov. 01, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) announces it has been granted european patent ep3866778 titled "combinations of inhibitors of influenza virus replication,” which covers the company's broad-spectrum oral pb2 inhibitor cc-42344 in combination with approved influenza antiviral drugs including tamiflu®, xofluza® or favipiravir. cocrystal recently announced the completion of enrollment in a phase 1 study with cc-42344 for the treatment of pandemic and seasonal influenza a, with topline study results expected later this year.
COCP Ratings Summary
COCP Quant Ranking